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INTRODUCTION 
Pregnancy is considered as an unique and physiologically normal 
episode in a women’s life. All pregnancies are at risk, while most pregnancies 
are uneventful. About 15% of pregnant women may develop a potentially life 
threatening complication in turn may require a major obstetrical intervention 
to survive. 
Labour is a naturally occurring phenomenon which usually starts on its 
own. It is defined as the spontaneous onset of regular and painful uterine 
contraction associated with a progressive effacement with dilatation of cervix 
and descent of presenting part, with or without a show or ruptured membrane. 
  In the era of modern obstetrics, where there has been a rapid 
advancement in all specialities, preterm labour remains an enigma for the 
obstetricians today. 
  Preterm labour is defined by WHO as the onset of labour after the 
period of viability, that is after 28wks of gestation and before 37 completed 
weeks or 259 days of pregnancy. 
 It is estimated that 15million preterm births occur worldwide, of which 
more than 1million died as result of their prematurity. Preterm birth is 
associated with significant perinatal morbidity and mortality rates. Moreover, 
it is associated with an increased risk of adverse metabolic outcomes in later 
life such as type 2 Diabetes mellitus, Hypertension, CAD & Stroke. The 
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mothers who delivered preterm infants also appeared to have increased risk 
of metabolic diseases later in life. 
Preterm birth affect over 10% of all pregnancies and leads to 
significant neonatal morbidity and mortality1. Prevention of viable 
spontaneous preterm birth and low birth weight through screening is one of 
the key aims of antenatal care as these have implications for the child, mother 
and society. If women can be identified to be at high risk of these adverse 
birth outcomes in early pregnancy, they can be targeted for more intensive 
antenatal surveillance and prophylactic interventions (primary prevention). 
CHOLESTEROL IN NORMAL PREGNANCY 
In normal pregnancy, the concentration of lipids, lipoproteins, 
apolipoproteins, are elevated. During early trimesters increased maternal fat 
accumulation is due to increased lipid synthesis, which subsequently leads to 
hypertriglyceridemia, occurring in late gestation. 
Increased insulin resistance and oestrogen stimulation lead to maternal 
hyperlipidemia. This is primarily due to enhanced entry of triglyceride rich 
lipoprotein (VLDL), in to the circulation rather than removal. Also the 
placental lipoprotein lipase normally increases as term approaches. 
The plasma TGL & Cholesterol levels increase during pregnancy & 
enhanced lipolytic activity play a key role in making free fatty acid available 
to the fetus. Hyperlipidemia is associated with endothelial dysfunction and 
also regarded as an instigator of inflammation and stress which is a significant 
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factor in preterm birth. Hence, elevated levels of cholesterol & triglycerides 
are a marker for increased risk of preterm labour, we have evaluated the 
elevated cholesterol as a predictor and its association on risk of preterm 
delivery. 
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LITERATURE 
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REVIEW OF LITERATURE 
DEFINITION:  Preterm labour is defined by WHO, as onset of labour 
after the period of viability, that is after 28 weeks and before 37 completed 
weeks of gestation or 259 days of pregnancy. 
Preterm birth is divided into several categories, based on weeks of 
gestational age:  
1) Extremely preterm (<28 weeks)  
2) Very preterm (28 to <32 weeks)    
3) Moderate to late preterm (32 to <37 weeks).   
Moderate preterm birth may be further split to focus on late preterm 
birth (34 - <37 completed weeks).  
Preterm birth is a syndrome with a variety of causes which can be classified 
into two broad subtypes:  
1. Spontaneous preterm birth (spontaneous onset of labour or following 
pre-labour premature rupture of membranes (PPROM)) and Provider-
initiated preterm birth (defined as induction of labour or elective 
caesarean birth before 37 completed weeks of gestation for maternal or 
fetal indications (both “urgent” and “discretionary”), or other non-
medical reasons. Around 60% of preterm births in the world occur in 
Africa and South Asia, and it is truly a global problem. India had 3 519 
100 preterm birth in 2010.4 Spontaneous rupture of membranes usually 
coincides with labour 
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INCIDENCE: 
The incidence of preterm births ranges from 5% -8% in most developed 
& developing countries. The incidence in India being 10% - 14%. But it is 
increasing worldwide which attributed to the raise in multiple gestations from 
assisted reproductive techniques, better dating scans and iatrogenic deliveries. 
SERUM LIPIDS: 
The major serum lipids include free (unesterified) fatty acids 
lysophospholipds , triglycerides , cholesterol (70% esterified with fatty acids) 
and phospholipids. Lipids are insoluble in aqueous solution, and are 
transported in plasma complexed with specific proteins or apoproteins. Free 
fatty acids and lysophospholipids bound by albumin; cholesterol, cholesterol 
esters and phospholipids exist as large lipid protein complexes called 
lipoproteins. 
Four major classes of lipoproteins are: 
1. CHLYMICRONS 
2. β LDL 
3. PRE β VLDL 
4. α HDL 
CHYLOMICRONS- These are assembled in intestinal mucosal cells from 
dietary lipids, primarily through triacylglycerol, which are degraded by 
lipoprotein lipase. 
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VLDL- Produced in the liver, composed predominantly of endogenous 
triacylglycerol (60%). Their function is to carry this lipid from the liver to 
peripheral tissues.  
LDL- These have a high concentration of cholesterol and cholesterol esters. 
Its primary function is to provide cholesterol to peripheral tissues or return it 
to the liver. 
HDL- These lipoproteins are present in the liver, small intestine. They take 
up cholesterol from non-hepatic (peripheral) tissues and return it to the liver 
by reverse transport, which is the primary mechanism by which HDL 
protects from atherosclerosis. 
Apolipoproteins function as structural components of lipoprotein 
particles, co factors for enzymes, ligands for cell surface receptors and 
determine the metabolic fate of the particle on which they reside. 
Six major classes of apolipoproteins:     
APO A1 – Major protein of HDL 
APO A2 – Unknown 
APO A5 – Biochemical and genetic marker of increased triglyceride 
concentration 
APO B48- Main lipoprotein of chylomicrons and LDL 
APO B100- Structural protein of VLDL, IDL, LDL for LDL receptor 
APO C2-Activates lipoprotein lipase, liberating fatty acid and 
monoglyceride from chylomicron  
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APO D- Component of HDL 
APO E- Involved in receptor recognition of IDL, chylomicron remnant by 
the liver.   
Serum lipids in pregnancy: 
Pregnancy is associated with significant variation in blood rheology 
consequent mainly to changes in lipoprotein profiles. Although these changes 
were first described by Bacquerel and Rodier the exact eludication of these 
changes is yet to be defined. An extensive review of literature revealed 
conflicting observation and implication of lipoprotein fractions metabolism 
in normal and abnormal pregnancies. All plasma lipoprotein fractions 
undergo striking increase during pregnancies. All lipids levels significantly 
increase in second and third trimester. 
 Total triglycerides increase 2-3 fold 
  Total cholesterol rises 50-60% above non – pregnant levels. 
  APO-B increases by 56% 
  Total cholesterol increases by 43% 
 LDL increases by 36% 
 APO-A increases by 32% 
 HDL increases by 25% in second trimester 
These changes are gradual and increase progressively throughout 
pregnancy after 25 weeks and peeks at term and return to pre pregnancy level 
6-8 weeks post-partum. 
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Quantitatively some lipoproteins such as HDL, LDL becomes TGL 
enriched. VLDL however increases cholesterol and TGL 2-5 fold compared 
to non-pregnant levels. LDL, after an initial drop at 8 weeks, rises steadily up 
to term by 45-50%. It is the only lipoprotein to remain elevated even after 8 
weeks of delivery irrespective to lactation. Post-partum measurements of 
lipids should be delayed for 6 months in women who did not have 
hypercholesterolemia prior to pregnancy. 
HDL is of a particular interest. Unlike other lipoproteins, which rises 
through 36 weeks, this lipoprotein reaches to its maximum level at mid 
gestation. It increases by 45% until 24 weeks and subsequently falls to 15% 
above non-pregnant level. These changes are confined to HDL sub fraction. 
HDL changes little. 
During early pregnancy, triglycerides, and dense LDL were higher than 
in the nonpregnant state. With advancing gestation, triglycerides increased 
and the distribution of apolipoprotein B-100-containing lipoproteins became 
increasingly dominated by the accumulation of very low density and 
intermediate density lipoproteins and buoyant, triglyceride-rich LDL. This is 
the first study that investigates LDL sub fractions in pregnancy using a 
method that strictly separates LDL sub fractions by virtue of density. The 
accumulation of buoyant, triglyceride-rich lipoproteins may be related to the 
down-regulation of maternal lipase activities by placental hormones. As a 
consequence, the metabolic changes of late pregnancy may result in an 
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increased flux of lipoprotein-derived lipids to the placenta, which, with 
advancing gestation, increasingly expresses receptors with a high affinity for 
triglyceride-rich lipoproteins. During gestation, the effect of oestrogen in 
enhancing very low density lipoprotein (VLDL) production and decreasing 
hepatic lipase activity plays a key role in the accumulation of triglycerides in 
lipoproteins of density higher than VLDL.  
 The physiology hyperlipidemia is of a potential significance from 
several point of view increase in plasma TGL may enhance available essential 
and non-essential TGL and free fatty acids for placental transfer to foetus 
a) LDL rise appears to be necessary for placental 
steroidogenesis and also for transplacental cholesterol 
transfer to foetus. 
b) TGL-increases may be a parameter of a general metabolic 
adaptation by mother to augment nutrient flow to foetus. 
The hyperlipidemia may stress maternal lipid homeostasis to an extent 
that sub clinical hyperlipedemia may be detectable analogous to the 
prediabetic recognition in women she develops gestational diabetes. 
In a review article herrara stressed that during early pregnancy   there 
is increased body fat accumulation associated with both hyperplasia and 
lipogenesis during late pregnancy that is an accelerated breakdown to fat 
depots, which play an important role in fetal development. 
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LIPIDS NON- 
PREGNANT 
ADULT 
FIRST 
TRIMESTER 
SECOND 
TRIMESTER 
THIRD 
TRIMESTER 
TOTAL 
CHOLESTEROL 
(Mg/Dl) 
< 200 141 – 210 176 – 299 219 – 349 
TRIGLCERIDES          
(Mg/dl) 
< 150 40 – 159 75 – 382 131 – 453 
 
Reference: WILLIAMS OBSTETRICS 24TH EDITION 
ETIOLOGY OF PRETERM LABOUR: 
The reasons for preterm birth have multiple interacting antecedents and 
contributing factors. Only when this complex factors causing prematurity are 
clearly understood, any attempt at prevention and management can be made.          
 50-60% Preterm births occur following spontaneous unexplained 
labour. 
 30-35% follow idiopathic preterm premature rupture of membranes 
(PPROM). 
 30% are iatrogenic, delivery for maternal or fetal indication. 
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CERVICAL INSUFFICIENCY 
This is defined as painless cervical effacement and dilation resulting in 
second trimester loss or preterm delivery. 
 Prior preterm labour and short cervical length  
 H/O cervical surgery – cone biopsy, large loop excision of 
transformation zone(LLETZ) laser ablation of the cervix 
 H/O obstetric trauma – Cervical laceration or injury during labour or 
delivery (spontaneous, vacuum, forceps or caesarean) 
 Multiple dilatation and evacuation 
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UTERINE CAUSES: 
 Congenital abnormalities 1-3% (septate and bicornuate) 
  Uterine over distension – multiple pregnancies, polyhydramnios 
INFECTIONS:  
 Subclinical – increased dominance of lactobacillus species 
 Intrauterine infection 
 Group B streptococcus  
 Chlamydia trachomatis  
 Mycoplasma hominis and ureaplasma urealyticum 
 Asymptomatic bacterial vaginosis and trichomonas vaginalis 
confers a modest risk of spontaneous preterm labour 
 Gardnerella vaginalis, fusobacterium (Gerber, 2003; Hillier, 
1988; Yoon, 1998) 
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 Extra uterine infection   
 High prematurity rate is associated with asymptomatic 
bacteruria and UTI (Robertson et al) 
 Other are systemic illness like pneumonia, 
pyelonephritis periodontal disease is associated with 
preterm labour. (Xiong X 2006) 
Connective Tissue Disorder: 
 Ehlers – Danlos Syndrome 
 Marfans Syndrome 
Fetal: 
 Congenital abnormalities 
Placental: 
 Abnormal placentation (causing decreased uteroplacental blood flow) 
 Anatomical abnormalities, Placenta Praevia 
 Abruptio placenta 
Hyperlipidemia: 
Catov et al reported that an elevation in maternal triglycerides or cholesterol 
level in early gestation was associated with a greater than 2 fold increased 
risk of preterm delivery. 
 
 
 
14 
 
Genetic: 
 CAP Genes (contraction associated proteins) in the myometrium – 
connexion 43, for oxytocin receptors (Korita, 2002; Lyall, 2002; 
Sooranna, 2004) 
 GRP (Gastrin Releasing Peptide) 
 TREK – 1 Potassium channel regulator (Buxton, 2010) 
 IL – 1 β, IL – 6, IL – 8, TNF α 
 MCP – 1 (Monocyte – chemotactic protein) 
 CCL – 2 (chemokine C-C motif ligande-2) 
 MMP – 1, MP – 2, MMP – 9 (matrix metallo proteinase) 
 
 
Pathophysiology: The control of parturition is achieved by complex 
integration of endocrine, paracrine and autocrine mechanism. 
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 Early uterine distention acts to initiate expression of Contraction 
Associated Proteins (CAP) and early activation placental – fetal – endocrine 
cascade. 
 Rising maternal serum levels placental derived corticotropin – 
releasing hormone (CRH), which works with adreno corticotropin hormone 
(ACTH). 
This increases adult & fetal adrenal steroid hormone production, causes 
initiation of fetal cortisol biosynthesis.   
 Rising levels of CRH stimulate the fetal adrenal 
dehydroepiandrosterome sulphate (DHEA- S) bio-synthesis. Which, acts as a 
substrate to increase maternal oestrogen (estriol). 
 The production of PGE2 and PGF 2 α by the enzymes phopholipases, 
15 hydroxy prostaglandin dehydrogenase may be the key in the balance 
between uterine quiescence and activity. The decidual activation and 
production of uterotropins is the penultimate event initiation of labor. 
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Lipid changes in preterm delivery:  
 Maternal hyperlipidemia is one of the most consistent and striking 
changes to take place in lipid metabolism during pregnancy. The mechanics 
responsible for these changes include, increased lipolytic and decreased LPL 
activities in adipose tissue. (Herrera and Collegues, 2006). The hepatic effects 
of estradiol and progesterone also play an important role (Desoye and 
associates 1987). 
 We have several hypothesis for why high FFA may increase risk of 
spontaneous preterm delivery. 
1. Maternal circulating FFAS can be transferred to the fetus across the 
placenta. In the support of this hypothesis was the observation that 
maternal plasma total FFAS were positively correlated with cord 
plasma FFAS. These include the essential FFAS and their 
metabolically important derivatives such as arachidonic acid a 
precursor of the eiscosanoids including prostacyclins and 
prostaglandins. 
2. It is known that prostaglandin play an important role by stimulating the 
uterine contractions that drive preterm delivery, Reece et al reported a 
higher proportion of maternal RBC and plasma arachidonic acid in 
preterm cases compared with controls. Thus this could be indirect 
evidence for excessive maternal arachidonic availability or 
mobilisation in preterm labor. 
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3. High FFAS may link to pro-inflammatory pathways. Preterm labor is 
recognised as an inflammatory phenomenon, even in the absence of 
infection, specific unsaturated fatty acids, particularly the essential 
fatty acid linoleic acid, which comes from the maternal diet.   
4. Selectively stimulate the development of a proinflammatory response 
in human endothelial cells studied in Vitro, increases in inflammatory 
cytokine formation in human decidua stimulate prostaglandins 
synthesis. Thus high maternal circulating FFA could be inked to 
inflammation a known risk factor for preterm delivery. 
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PREDISPOSING FACTORS: 
1. Previous Preterm Birth 
The recurrent risk for women whose first delivery was preterm was 
increased 3 fold (Spong, 2007)  
Birth Outcome Recurrence Risk 
1st Birth > 35 weeks 5% 
1st Birth < 35 weeks 16% 
1st & 2nd Birth < 34 weeks 41% 
(Williams Obstetrics 24th edition) 
2. Previous Threatened Abortion 
3. Cervical incompetence 
4. Uterine anomalies  
5. Pregnancy complications 
 Hydramnios 
 Multiple pregnancies 
 Preclampsia 
 Antepartum haemorrhage 
6. Birth Defects was found to be associated with preterm birth and low 
birth weight (FASTER trial) 
7. Stress 
 Physical work and psychological stress are associated with 
increased preterm birth (Lockwood, 1999; Petrglia, 2010; Wadhwa, 
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2010). Also preterm birth is increased in women living alone and those 
subjected physical abuse.  
8. Life Style Factors  
 Cigarette smoking, illicit drug abuse (cocaine) (Berns, 2002) 
 Poor nutrition, Inadequate maternal weight gain 
 Over weight and obese mothers (Cnattingius, 2013) 
 Young age or advance maternal age (under 17 and over 35) 
(Lumley JM et al 1993) 
 Short stature  
 Low social economic status tend to be less educated regarding 
general perinatal and antenatal care (Goffinet F 2005) 
 Occupational factors - Long working hours and hard physical 
labor 
9. Inter-pregnancy Interval 
Intervals < 18 months and > 59 months were associated with increased 
risk for preterm birth and small for gestational age (Conde – Agudelo, 
2006) 
10. Periodontal Disease 
Gum inflammation was significantly associated with preterm birth 
(ODDS ratio 2.83) 
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11. Race 
The incidence is greater in non-Hispanic black and American Indian / 
Alaska native (Collins, 2007) 
 
NEONATAL COMPLICATIONS: 
 Approximately 70% neonatal deaths, 36% infant deaths, 25 to 50% 
cases of long term neurological impairment in children ca be attributed to 
preterm birth (ACOG, 2016) 
 Birth asphyxia  
 Respiratory distress syndrome 
 Hyaline membrane disease 
 It is the most important threat when the baby is delivered before 
37 weeks of gestation. The incidence RDS is estimated to decrease 
from 15% at 34 weeks to below 1% at 37 weeks. The incidence RDS 
was 22.5% in 33 weeks and 5.8% in 34 weeks. It was relatively low 
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after 34 weeks, it still affects neonates upto 36 weeks with incidence 
of 10.4% in 35 weeks and 1.5% in 36 weeks. The incidence of RDS 
was nearly 4 – 5 fold higher in the preterm patients than in term 
patients. 
 Apneoa of prematurity 
 Broncho pulmonary dysplasia 
 Neurological damage 
 Cerebral palsy 
 It is long term sequelae especially when complicated with intra 
ventricular haemorrhage, intra partum fetal acidosis and hypoxia.   
 Neuro developmental delay, learning difficulties 
 Reduced growth potential 
 Sensorineural deafness 
 Hyperbilirubinemia  
 Necrotizing enterocolitis 
 Failure to thrive 
 Hospital acquired infection  
 Retinopathy of prematurity 
 Retrolental fibroplasia 
 Patent ductus arteriosus 
 Anemia of prematurity 
 Recurrent respiratory infection 
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 Metabolic problem 
 Sudden infant death syndrome 
The cost of preterm birth can be measured in terms of mortality and 
morbidity and in short term and long term financial costs which increase with 
lower gestational age. The components at the costs are nursery, medical staff, 
stay in neonatal intensive care unit and treatment. Such as ventilation, 
artificial surfactant, recombinant erythropoietin and surgical procedures. The 
long term financial implications are unknown if the child is handicapped 
either physical or mental. 
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PREDICTION OF PRETERM LABOUR 
Cervical assessment: Asymptomatic cervical dilatation after mid 
pregnancy has gained as a risk factor for preterm delivery. (Copper,1995; 
Pereira,2007) 
 Owen and Colleagues (2003) concluded that the value of cervical 
length to predict preterm birth before 35 weeks is apparent only in women at 
high risk for preterm birth. 
 Cervical Length analysis using transvaginal sonography is safe, highly 
reproducible and more predictive than transabdominal sonography. TVS is 
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not affected by maternal obesity cervix position or shadowing from fetal 
presenting part. 
 Goldenberg and Co-workers found the main cervical length of less than 
25mm at 24 weeks of gestation to be a strong predictor of preterm birth. 
 A positive predictive value of 70% and sensitivity of 60 to 80% is 
observed with a transcervical ultrasound cervical length (TVS CL) of less 
than 25mm between 14 to 18 weeks of gestation. 
 Ultrasound is a better modality than digital evaluation of cervical 
length because the upper half of cervix which cannot be reached digitally can 
be measured by ultra-sonogram. 
 Fetal breathing movements: Absence of fetal breathing movement on 
ultrasound done at the time of admission on women who presented with 
threatened preterm labor was also found to be accurate test in predicting 
spontaneous preterm birth. 
Uterine Activity Monitoring 
 ACOG (1995) has concluded   that for most patients home uterine 
monitoring is not better than frequent nursing contact and support. IAMS and 
Associates (2002) found that no contraction pattern efficiently predicted 
preterm birth. 
Only patient, who cannot recognize adequately the presence of 
contractions like multifetal gestation and other over distended uterus may 
benefit from home uterine monitoring. 
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Fibronectins 
Fetal fibronectin is an extracellular glycoprotein secreted by chorionic 
tissue at maternal and fetal interface and is present in large quantities in 
amniotic fluid.  The presence of fetal fibronectin in cervicovaginal secretions 
in late second and early third trimester has been proposed as a specific 
predictor of preterm labor (Lock wood and coworkers, 1991). It represents 
disruption of choriodecidul interface which can be caused by preterm labor. 
It can be detected in the ectocervix and vagina,is measured by ELISA with 
FDC-6 Monoclonal antibody  and values exceeding 50ng/ml are considered 
positive result. However, of concern is the high false positive rate if there is 
contamination with amniotic fluid, semen, maternal blood and in patients with 
cerclage. A positive test is associated with an increased likelihood of birth 
before 34 weeks of gestation within 14 days of test with a positive predictive 
value of 16%. 
The high negative predictive value of fetal fibronectin can be used to 
influence management (Honest h et al 2002). 
In symptomatic women the group found that cervicovaginal fetal 
fibronectin and absence of fetal breathing moments of ultrasonogram are 
likely to be accurate in predicting preterm birth. 
New Predictors of Preterm Labor 
 Cervical electrography 
 Aspiration and CCI 
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 Quantitative USG and Beam Steering 
 Shear wave speed estimation 
Biochemical Markers 
1. Salivary oestriol: progesterone ratio 
2. Salivary oestriol >1.8/ml before 34 weeks has a sensitivity of 68% 
and specificity of 76% for preterm labor before 35 weeks of 
gestation (Darne et all) 
3. Serum collagenase 
4. Tissue inhibitor if metalloproteinase (TIMP) / Matrix 
5. Relaxin 
6. Corticotrophin Releasing Hormone (CRH) 
7. Human chorionic gonadotropin 
8. Mediators of inflammation and infection 
a) C-Reactive protein 
b) Granulocyte elastase 
c) Cytokines (I1-6, TNF) 
d) Amniotic fluid glucose concentration 
e) Zinc and Lipocortin – 1 (Romeo R et al) 
f) Positive cultures 
g) Granulocyte colony stimulating factor 
These are not practically helpful in prediction of preterm labor 
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DIAGNOSIS OF PRETERM LABOR         
Preterm labour is defined as regular contractions (6/60m) with 
documented cervical changes before completion of 37 weeks of gestation (or) 
cervical dilatation of >2cm and 75% effacement with history of contractions. 
SYMPTOMS OF PRETERM LABOUR 
 Persistent uterine contractions 
 Low, dull back ache 
 Pressure (Feels like baby is pushing down) 
 Intermittent Abdominal cramping 
 Increase or change in vaginal discharge 
 Vaginal spotting/bleeding 
Assessment of Patients in Preterm Labor 
 Labs-CBC, UA +/- culture, electrolytes 
 Sterile speculum exam obtaining cultures for group B strep, BV, GC, 
Chlamydia, obtain fetal fibronectin 
 Cervical length measurement 
 The last thing is the cervical digital exam 
1. Pelvic examination 
2. Ultrasonogram 
 Ultrasonographic assessment in preterm labor 
 Fetal viability 
 Gestational age 
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 Estimated fetal weight 
 Transvaginal cervical assessment 
CERVICAL ULTRSOUND 
 Cervical length <20mm/contraction criteria-preterm 
 Cervical length 20-30mm/contraction criteria-    probable 
 Cervical length >30mm- preterm labor unlikely regardless of 
contraction frequency 
 Fetal breathing movements 
 Amniotic fluid volume 
 Number of fetus 
 Fetal presentation and lie 
 Fetal movements and tone 
 Fetal anomaly  
 Placental localisation and morphology 
 Uterine Fibroid and adnexal mass 
3. Tococardiography  
The amplitude, duration, shapes of contraction frequency and basal 
tone and monitored. The uterine activity is monitored. Changes in FHR (Fetal 
Heart Rate) pattern occurring in preterm labor is normally due to immaturity 
of cardiovascular system. Repetitive late decelerations, absent variability 
decelerations are sign of placental insufficiency. 
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PREVENTION OF PRETERM LABOR
 
I Basic care: 
a) Support system of family should be developed 
b)  Suggestions on coping with physical and mental stresses of 
maintaining a pregnancy should be described 
c) Education, supportive services from health care provided and financial 
issues are of common concern 
d) Behavioural and Life style modification 
i. Smoking cessation (Burguet et al) 
ii. Adequate nutrition 
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II Bed rest and Hydration  
 Although bedrest and hydration are widely used as the first step of 
prevention and treatment, there is no evidence that this practice is beneficial 
(Freda MC et al, Goldenberg RL et al.,) 
 Bed rest should be advised with caution after evaluating its benefits & 
risks in an individual, and not routinely keeping in mind its adverse like 
venous thrombosis and pulmonary edema.(Kovacevich,2000) 
Women with activity restriction were nearly 2.5 times more likely to 
have a preterm birth before 34 weeks.(Grobman&associates 2013) 
Aggressive Treatment of Cervicovaginal Infection 
 According to ORACLE TRIAL II (2008) Kenyon & associates routine 
administration of antibiotics for treatment of preterm labour with intact 
membranes is not recommended.  
25- 40% PTL results from subclinical intrauterine infections 
  GBS prophylaxis 
  Inj. AMPICILLIN 2g IV initial dose then 1g every 6 hrs till delivery 
(or) 250mg ORALLY every 8hrs FOR 7 DAYS 
  Inj. Cefazolin,2g IV initial dose then 1g every 8 hrs 
 oral erythromycin 250 mg 4 times a day for a maximum of 10 days or 
until the woman is in established labour (whichever is sooner). 
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 Who cannot tolerate erythromycin or in whom erythromycin is 
contraindicated, consider oral penicillin for a maximum of 10 days or 
until the woman is in established labour (whichever is sooner). 
 Do not offer women with P-PROM co-amoxiclav as prophylaxis for 
intrauterine infection due to increased risk of cerebral palsy. 
 Antibiotics reduce risk of persistent infection but did not have 
reduction in risk of Preterm birth. 
 Bacterial vaginosis has been consistently associated with a 1.5 to 3 
times increased risk of spontaneous preterm birth. But the efficacy of 
treatment in reduction of preterm births is conflicting (Goldenberg R, 
et al, 1998). But recent systematic review by Varma R, Gupta JK 2006 
concluded that screening and treatment of asymptomatic bacteruria and 
bacterial vaginosis in low risk population groups may reduce the rate 
of preterm deliveries. 
Cervical Encerclage 
 A short cervix diagnosed by ultrasound in asymptomatic women may 
be an indication for cerclage. The role of cervical for the prevention of 
preterm delivery is now disputed. A number of systematic reviews which 
demonstrate a trend towards reduction in preterm delivers before 34 weeks in 
high risk women who had cerclage compared to those managed expectantly 
(Honest H, et, al) 
 
32 
 
PROPHYLATIC CERCLAGE: 
  H/O 2nd trimester loss ass with painless cervical dilation. 
  H/O  cerclage in previous pregnancy  
  Cervix length less than 2.5cm before 24 w(TVS) 
  H/O spontaneous preterm birth(less than 34 w) 
  Currently has painless cervical dilation 
 Consider 'rescue' cervical cerclage  (Terkildsen&workers,2003) for 
women between 16+0 and 27+6 weeks of pregnancy with a dilated 
cervix and exposed, unruptured fetal membranes: 
 FAILURE>4CM dilatation 
 Explain about the risks VS benefits 
Progesterone 
 Weekly intramuscular administration to women at high risk for preterm 
labor resulted in lower rates of preterm birth and perinatal mortality when 
compared with that placebo, Meis and collaboraters (2003). The dose used by 
Meis et al was 250mg of 17 hydroxy progesterone caproate, intramuscularly 
every week from 20 to 36 weeks. 
A Cochrane Systematic review in 2006 by Dodd JM et al found that 
the use of progesterone on women with history of spontaneous preterm birth 
resulted in a reduction in risk of preterm birth before 34 weeks of gestation 
and infant birth weight than 2500 grams. But the dose, route of administration 
and time commencement of therapy has not been arrived conclusively by this 
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study for need of further information. For women with threatened preterm 
labor the role progesterone is uncertain as per this review. 
Randomized Trials of Progestin Compounds Given Prophylactically to 
Prevent Preterm Labor 
Investigator 
Cervical 
Length 
Progestin Compound Progestin vs Placebo 
Fonseca (2007) < 15 mm 
Progesterone, 200 mg 
vaginal capsules daily 
Delivery < 34 weeks: 
19% vs 34% 
P = .02 
Hassan (2011) 10 – 20 mm 
Progesterone, 90 mg 
vaginal gel daily 
Delivery < 33 weeks: 
9% vs 16% 
P = .02 
Grobman 
(2012) 
< 30mm 
17 – OHPC, 250 mg IM 
weekly 
Delivery < 37 weeks: 
25% vs 24% 
P = NS 
Williams 24th Edition 
 Offer a choice of prophylactic vaginal progesterone or /AND 
prophylactic cervical cerclage to women: 
 with a history of spontaneous preterm birth or mid-trimester loss 
between 16+0 and 34+0 weeks of pregnancy and 
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 in whom a transvaginal ultrasound scan has been carried out between 
16+0 and 24+0 weeks of pregnancy that reveals a cervical length of less 
than <25 mm 
MANAGEMENT OF PRETERM LABOR 
Hydration and Bedrest 
Steroids 
 In 1995, a national Institute of Health Consensus development, panel 
recommended corticosteroids for fetal lung maturation in preterm labor. Since 
then there has been nearly universal acceptance and implementation of these 
recommendations. 
 Consider maternal corticosteroids for women between 23 TO 
35+6 weeks of pregnancy who are in suspected, diagnosed or 
established PTL, are having a planned PTB, have P-PROM. 
 REDUCES RISK OF  
 RDS-34% 
 IVH-46%, 
 NEONATAL DEATH-31% 
 SINGLE COURSE- at 24-34 WEEKS 
 GREATEST BENEFIT 48 Hrs -7 DAYS 
 RESCUE COURSE 
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 Administer a course of ANCS in patients who have received 
prior course, but do not deliver in 7-14 days, upto 34 wks may 
receive a repeat course 
 RCOG 
 SINGLE COURSE  24 – 35WKS 
 AII Antenatal , for whom elective LSCS planned prior to 38 
wks. 
 Recommended regimens includes a single course of two doses of 12mg 
of betamethasone given intramuscularly 24 hours apart, or four doses of 6mg 
of dexamethasone given intramuscularly 12 hours apart. 
 Although benefit on neonatal outcome is maximum between 24 hours 
and 7 days after initiation of therapy, steroids confer survival advantages even 
when delivery occurs within 24 hours. Therefore, treatment should not be 
withheld when delivery is probable within 24 hours 
Tocolysis: 
 Tocolysis is pharmacological suppression of uterine activity 
Indication: 
 Preterm delivery is a major cause of perinatal morbidity and mortality. 
Tocolytic agents are effective in reducing the likelihood of delivery within 48 
hours but do not reduce the overall risk of preterm delivery. 
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Consideration should be given for administration of tocolytics to all 
women experiencing preterm labor when there is a delay in delivery 
 To permit in – utero transfers to a tertiary perinatal centre for multi 
displinary management (obstetrician, neonatologist, anaesthetists) 
 To gain upto 48 hours to allow for the administration of corticosteroid 
to enhance pulmonary maturity. 
BETA SYMPATHOMIMETICS 
Caritis et al 1976, noted that small doses of epinephrine inhibited 
uterine hyperactivity. Efforts to produce an epinephrine like compound which 
lacked the cardiovascular stimulant effect culminated in the synthesis if β 
agonists. 
 I generation: - Isoxsuprine, Orciperenaline, isoprenaline 
 II generation: - Ritodrine, terbutaline, fenoterol. 
The most commonly used β2 agonist for tocolysis is ritodrine, then are 
terbutaline and salbutamol. 
Ritodrine: 
 Ritodrine infusion is started at a dose of 50µb/min and increased every 
20 minutes until uterus is quiescent or side limit of dose. Side effects are 
palpitations, tremor, nausea, headache, chest pain, dyspnoea, pulmonary 
edema, hypokalemia, myocardial ischemia, arrhythmias. 
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Terbutaline: 
Not used as much as ritodrine, but is effective in temporarily 
suppressing contraction when given parenterally. 
Intravenous dose is 5-10µg/min, increased every 10-15 min to a 
maximum of 80µg. 2.5 – 5mg is given orally every 4-6 hours & 250µg 
subcutaneously every 20 – 30 min given as 4-6 doses. Terbutaline has higher 
a risk of hyperglycemia than ritodrine. Other side effects ae similar. But β2 
agonists are no longer the first choice of drugs for tocolysis because of their 
side effects (RCOG Clinical Guide Lines, 2002 and Anatayanonth et al, 2004) 
Contraindications of β2 agonist: 
 Symptomatic cardiac disease especially ventricular outflow 
obstruction 
 Conduction disturbance 
 Hyperthyroidism 
 Sickle cell disease 
 Uncontrolled maternal diabetes mellitus 
 Chorioamnionitis 
 Eclampsia or severe preeclampsia 
 Multifetal gestation 
 Severe obstetrical bleeding 
 
 
38 
 
MAGNESIUM SULPHATE 
MgSO4 uncouples the depolarisation contraction coupling. During the 
depolarisation of myometrial cells, Mg++ competes with ca+ to for entry into 
the cell causing less intracellular ca+ to participate in actin –myosin 
interaction during smooth muscle contraction. It affects neural transmission 
by modifying acetyl choline release and sensitivity at motor end plate. 
Contractility is inhibited at serum level of 5-8 mEq/dl. Deep tendon 
reflexes are lost at 9-13 mEq/dl. Respiratory depression occurs at >14 mEq/dl. 
Dosage: Intravenous loading dose of 4g administered over 20 mins 
followed by maintenance dose of 1-2 g/hr. 
Side effects include flushing, dizziness, nausea, lethargy, chest 
tightness, Hypocalcaemia, Pulmonary edema, respiratory depression and 
depressed motor, respiratory activity in fetus. It is contraindicated in 
myasthenia gravis, heart block, renal disease, recent myocardial infarction. 
Magnesium sulphate is an ineffective tocolytic agent as shown by a 
Cochrane systematic review (Crowther et al, 2002., Cox etal 1990) 
PROSTAGLANDIN SYNTHETASE INHIBTORS 
Drugs like aspirin, indomethacin, naproxen, fenamate were found to 
inhibit the prostaglandin synthesis, decrease the myometrial gap junction and 
decrease the influx of calcium. 
Maternal side effects include nausea, vomiting, drug rash headache, 
gastritis, diarrhoea. In fetus it produces constriction of ducts arteriosus, 
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pulmonary hypertension and oligohydramnios. Intraventricular haemorrhage, 
necrotising entercolitis have also been reported. 
They are effective as single dose in inhibiting the myometrial activity 
in many women at term (Reiss et al, 1997). Tow randomised trials which 
compared the effect of indomethacin and placebo in delaying delivery showed 
significant delay at 48 hours and at 7 -10 days. 
Comparison with agonists show similar efficacy, but a better side effect 
profile (RCOG GUIDELINE 2002). However, their use is limited because of 
their effects in the fetus. 
CALCIUM CHANNEL BLOCKERS 
They are heterogeneous group of organic compounds that inhibit the 
influx of extracellular calcium across the cell membrane during inward 
calcium current of action potential. They block the voltage sensitive L type of 
calcium channels. They also inhibit the release of intracellulat calcium from 
the sarcoplasmic reticulum. Thus they reduce the tone of smooth muscles, the 
commonly used drug Nifedipine is a potent inhibitor of myometrial 
contractions in non-pregnant, pregnant and post-partum uterus (Anderson et 
al, 1979) 
 Consider nifedipine for tocolysis for women between 24+0 and 36 
weeks of pregnancy who have intact membranes and are in suspected 
PTL 
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 If nifedipine is contraindicated, offer oxytocin receptor antagonists for 
tocolysis. 
Treatment Regime: 
The optimal dosing regimen of Nifedipine has not yet defined. Read 
and Wellby 1986, George et al 1997, showed that an initial dose of 30mg 
followed by 20mg 8th hourly for 3 days, reported a 75% successful tocolysis 
in 71% and 76% respectively. The tocolytic regimen given in Obsetrics and 
Gynaecology Clinics of North America (Andrienne Z et al) is loading dose 
30 mg orally and maintenance dose of 10 -20 mg orally every 4-6 hrs. 
In Clinical Obstetrics and Gynaecology 2000, Amy E et al found the 
following dosing regimens in various study protocols. Most administered a 
initial loading dose of 30mg of oral nifedipine followed by 10mg to 20mg 
dose every 4 to 6 hrs,upto a maximum dose of 160mg.  Sublingual Nifedipine 
loading doses are no longer advised. 
OXYTOCIN ANTAGONISTS (ATOSIBAN) 
Oxytocin is fundamentally involved in the mechanism of labour. 
Oxytocin receptors are crucial for the onset of labor. There will be increase in 
myometrial oxytocin receptors in labor. The analogue competitively blocks 
the oxytocin receptors and inhibits preterm labor. 
Atosiban acts only on myometrium/myoepithelial tissue (MOST 
UTEROSPECIFIC) Atosiban is given intravenously 6.75mg bolus over one 
minute followed by infusion at 18mg/hr for 3 hrs and then 6mg/hr for upto 45 
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hrs. Duration of treatment should not exceed 48 hrs and the dose should not 
exceed 330mg of atosiban. Side effects are nausea, chest pain, vomiting and 
dyspnoea. Compared to β agonist atosiban has similar efficacy but a better 
side effect profile. 
Royal College of Obstetricians and Gynaecologists 2002, suggest that 
if tocolytics are administered, the first choice should be oxytocin antagonists 
or Nifedipine. But compared with other tocolytics atosiban therapy is costly. 
NITRIC OXIDE DONORS (GLYCERYL TRINITRATE) 
Nitric oxide is a potent endogenous hormone causing smooth muscle 
relaxation. The No donors inhibit corticotrophin releasing hormone secretion 
which acts as a promoter of parturition. 10mg of Glyceryl Trinitrate patch is 
applied over the fundal region of maternal abdomen. If tocolysis is not 
achieved in one hour, another 10mg patch can be applied to a maximum dose 
of 20mg in 24 hours. Cochrane review (2000) by Duckitt K et al showed that 
nitroglycerine did not delay delivery or improve neonatal outcome when 
compare with placebo, no treatment or alternative tocolytics. 
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K+ CHANNEL OPENERS: 
Diazoxide is a medication structurally related to thiazide diuretics that 
is used in treatment of hypertensive crisis. It inhibits contractility of smooth 
muscles there by rendering myometrial quiescence. 
 Dosage is 5mg/kg, given intravenously slowly in 15-30 minutes. The 
drug is diluted in half normal saline. It can also be given in blouses of 50 – 
100 mg every 5 minutes. Side effects are hypotension, tachycardia, 
hyperglycemia and decreased uteroplacental blood flow secondary to 
maternal hypotension. The fetal side effects are hypoglycaemia and fetal 
distress secondary to maternal hypotension. Further evaluation of this newer 
group of tocolytic drugs is needed. 
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AIM OF THE STUDY 
 
 To evaluate the association of elevated cholesterol levels at 14 to 24 
weeks gestation in uncomplicated pregnancy and preterm delivery. To 
associate the elevated levels of cholesterol as predictor of preterm delivery 
Primary Objective:  
To determine the association between elevated Serum Cholesterol in 
Pregnancy & Pre-term Births 
Secondary Objective:  
To determine the association between elevated Serum Cholesterol in 
Pregnancy & Pre-term Births 
                     
 
 
 
 
 
 
 
 
 
  
 
 
MATERIALS AND 
METHODS 
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MATERIALS AND METHODS 
 
The study group includes 300 healthy pregnant women, fasting 
cholesterol levels during 14 to 24 weeks gestation who have come to antenatal 
check-up at the Department of Obstetrics and Gynaecology, Madras 
Medical College, during the period August 2016 to July 2017. 
Only those patients we could follow up to term and planning delivery 
at IOG were included in the study. The biochemical investigations were done 
at the Institute of Biochemistry, MMC. The hospital ethical committee 
approved the study. 
Out of 322 antenatal mothers selected on the basis of inclusion and 
exclusion criteria 22 were excluded during the study for various reasons. 4 
developed PIH, 7 developed Gestational diabetes Mellitus, one case was a 
multiple pregnancy,2 were abruption placenta, and 8 were lost to follow up. 
INCLUSION CRITERIA: 
Age = 17 – 35 years 
Gestational age = from participants last menstrual period or modified by 
USG. 
EXCLUSION CRITERIA: 
 GDM 
 Pregnancy included Hypertension 
 Previous H/O preterm delivery  
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 Multiple pregnancy 
 Hydramnios 
 Cervical Incompetence 
 Pre-existing medical disease 
 Cardiovascular disorder 
 Renal disorder 
 Congenital anomalies of fetus 
 Smoking 
 Unknown last menstrual  period 
STUDY METHOD: 
The design of the study prospective study. In all these antenatal 
mothers detailed history with special reference to diet and habits, followed by 
complete general and obstetric examination were done. The purpose of 
interrogation and investigation was explained to every patient and her 
informed consent obtained. 
GENERAL EXAMINATION: 
Height, weight, pulse, blood pressure, edema, anemia, cardiovascular, 
respiratory and central nervous system disorder were examined. 
OBSTETRIC EXAMINATION: Per Abdomen Examination 
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PROCEDURE: 
From all the antenatal mothers who were included in the study, blood 
sample was taken after overnight fasting. 
Under strict aseptic precaution blood was obtained for other 
investigations by venepuncture. 
Cholesterol between 14 to 24 weeks gestation were obtained after 
overnight fast. The patients were followed till delivery. 
LABORATORY TESTS: 
The blood samples for cholesterol were collected and analysed. 
TOTAL CHOLESTEROL: 
Serum total cholesterol were determined by automated enzymatic 
method using Burstein, Lopes – Vivella CHOD – PAP method. Chylomicrons 
are precipitated by adding phosphotungstic acid solution and magnesium ion 
to the sample. Centrifugation leaves HDL in supernatant fluid. The 
cholesterol content is determined enzymatically. 
PROCEDURE: 
200ml of sample with 500ml of precipitant fluid were mixed together 
and a precipitate is obtained by allowing it to stand for 10 minutes at room 
temperature. This is then centrifuged and 100 ml of the supernatant fluid is 
mixed with 1000ml of reagent solution. Phosphotungstic acid. The results are 
obtained by analysing the absorbance of sample and standard using semi auto 
analyser. 
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PRINCIPLE: 
The formation of coloured phenazone compound with the reagent 
forms the basis of the test. 
Sample of 10 ml and 1000ml of reagent are mixed and incubated for 5 
minutes at 37C and absorbance of sample measured within 60 minutes. 
Results were analysed in semi auto analyser (ERBAKEMP). 
 
 
 
  
  
  
 
 
OBSERVATION AND 
ANALYSIS 
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OBSERVATION AND ANALYSIS 
Statistical Tools: 
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of computer 
using Epidemiological Information Package (EPI 2010) developed by Centre 
for Disease Control, Atlanta. 
Using this software range, frequencies, percentages, means, standard 
deviation, chi square and ‘p’ values were calculated. Kruskul Wallis chi-
square test was used to test the significance of difference between quantitative 
variables and Yale’s chi square test for qualitative variables and Yate’s chi 
square test for qualitative variables. A ‘p’ value less than 0.05 is taken to 
denote significant relationship. 
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RESULTS 
A. Profile of Cases Studied 
Table 1. Age distribution 
 
AGE_GROUP Frequency Percent 
19-21 YEARS 120 40.0 
22-24 YEARS 142 47.3 
25-28 YEARS 38 12.7 
Total 300 100.0 
 
Descriptive Statistics 
 N Minimum Maximum Mean Std. Deviation 
AGE 300 19.00 28.00 22.13 2.00451 
      
 
Majority of the women included in the study were 22 to 24 years old. 
The study group had mean age of 22.13 years, standard deviation of 2.004 
years. 
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AGE DISTRIBUTION 
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Table 2. Obstetric Code 
 
OBSTETRIC_CODE Frequency Percent 
PRIMI 140 46.7 
G2PIL1 160 53.3 
Total 300 100.0 
 
46.7% of mothers included in the study were primis. Remaining 
mothers (53.3%) were second gravida mothers. 
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OBSTETRIC CODE 
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Table 3 
Gestational age at which blood collected for analysis 
 
BLOOD_COLLECTION_WEEKS Frequency Percent 
16.00 2 0.7 
18.00 72 24.0 
20.00 75 25.0 
22.00 78 26.0 
24.00 73 24.3 
Total 300 100.0 
 
Serum cholesterol levels were assessed for 300 mothers during 16 to 
24 weeks of gestation. 
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Table 4 
Serum Cholesterol Level 
 
Serum Cholesterol Level Frequency Percentage 
Normal 281 93.7% 
Abnormal 19 6.3% 
 
About 19 mothers (6.3%) had abnormal cholesterol levels, and the 
study group had a mean serum cholesterol level of 266.2 mg/dl 
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SERUM CHOLESTEROL LEVEL 
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Table 5 
Outcome of delivery - Preterm / Term 
 
Outcome of delivery Frequency Percent 
TERM 277 92.3 
PRE TERM 23 7.7 
Total 300 100.0 
 
Out of the 300 mothers included in the study, 23 mothers (around 
7.7%) had preterm delivery. 
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OUTCOME OF DELIVERY 
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Table 6 
Relation between cholesterol & other variables with outcome of delivery 
 
Age of Mother and Outcome of delivery 
 
OUTCOME 
Total 
PRE 
TERM TERM 
AGE_GROUP 19-21 YEARS Count 5 97 102 
% within  
OUTCOME 
21.74% 35.02% 34.00% 
22-24 YEARS Count 6 126 132 
% within  
OUTCOME 
26.09% 45.49% 44.00% 
25-28 YEARS Count 12 54 66 
% within  
OUTCOME 
52.17% 19.49% 22.00% 
Total Count 23 277 300 
% within  
OUTCOME 
100.0% 
100.00% 100.00% 
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Table 7 
Obstetric code and outcome of delivery 
 
OUTCOME 
Total PRE TERM TERM 
OBSTETRIC 
CODE 
G2PIL1 Count 15 145 160 
% within 
OUTCOME 
65.2% 52.3% 53.3% 
PRIMI Count 8 132 140 
% within 
OUTCOME 
34.8% 47.7% 46.7% 
Total Count 23 277 300 
% within 
OUTCOME 
100.0% 100.0% 100.0% 
 
Pearson Chi-Square =1.413, P=0.234 
The percentage of pre-term deliveries among PRIMIs and second 
Gravida did not have statistical significant difference (p = 0.234) 
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Table 8 
Serum cholesterol and Outcome of delivery 
 
OUTCOME 
Total TERM PRETERM 
SC NORMAL <200 Count 104 6 110 
% within  
OUTCOME 
94.5% 5.5% 100% 
200-300 Count 166 5 171 
% within  
OUTCOME 
97.1% 2.9% 100% 
ABOVE 300 Count 7 12 19 
% within  
OUTCOME 
36.8% 63.2% 100% 
Total Count 277 23 300 
% within  
OUTCOME 
92.3% 7.7% 100.0% 
Pearson Chi-Square =88.84** P<0.0001 
Mothers with normal cholesterol values had 96.1% term delivery and 
around 3.9% had pre-term delivery, whereas mothers with abnormal 
cholesterol had 63.1% pre-term delivery. The difference is statistically 
significant (p < 0.0001) 
64 
 
 
 
SERUM CHOLESTEROL AND 
OUTCOME OF DELIVERY 
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Table 9 
Outcome of delivery vs Mode of delivery 
  Mode of Delivery 
Outcome of delivery 
  Normal  LSCS 
Term 
Count 168 109 
%age 60.6% 39.4% 
Pre-Term 
Count 19 4 
%age 82.6% 17.4% 
Pearson Chi-Square =4.36, P<0.05 
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Table 10 
  Fetal Weight (in Kgs) 
Outcome of 
Delivery 
# Mean SD 
TERM 277 2.7812 0.2105 
PRETERM 23 1.9541 0.3869 
 
The mean fetal weight of children delivered at term are significantly 
higher than that of pre-term children. 
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Table 11 
Outcome of delivery and NICU Admissions 
 
OUTCOME1 
Total PRE TERM TERM 
NICU_ 
ADMISSION 
NO Count 5 270 275 
% within  
OUTCOME1 
21.7% 97.5% 91.7% 
YES Count 18 7 25 
% within  
OUTCOME1 
78.3% 2.5% 8.3% 
Total Count 23 277 300 
% within  
OUTCOME1 
100.0% 100.0% 100.0% 
Person Chi-Square =159.45** P<0.0001 
The outcome of deliveries had significant association with NICU 
admissions (p< 0.0001) 
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DISCUSSION 
 Preterm delivery is defined as by WHO, birth occurring prior to 37 
completed weeks gestation. The incidence in India is 10 – 12% and developed 
countries is 5% to 10%. 
 Serum cholesterol levels increase during pregnancy & is necessary 
uteroplacental vascularisation, placental transport functions. Hyperlipidaemia 
is also regarded as an instigator of inflammation and stress, which is a 
significant factor in preterm birth. 
 In this study, 300 antenatal mothers with singleton pregnancy between 
the gestational age of 14-24 weeks were enrolled. After detailed history taking 
and physical examination, fasting maternal serum cholesterol levels were 
estimated and the patients were followed till delivery (preterm / term). 
 The incidence of preterm delivery, mode of delivery, gestational age at 
delivery was noted; to study the linear trend and to estimate if there is a dose 
response relationship between increasing cholesterol values and gestational 
age at delivery. 
American medical journal OBSTETRICS AND GYNAECOLOGY 
2007, December 197 (6) 610. Cator jim, Bodnar studied in early pregnancy 
lipid concentration and spontaneous preterm birth. 
In that case control study of women with spontaneous preterm birth, 
cholesterol, high density lipoprotein, low density lipoprotein, triglycerides 
were evaluated. Lipid concentration and gestational changes as well as risk 
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for preterm birth were evaluated in women who delivered < 34 weeks (n=23) 
> or = 34 (n=67) and > or = 37 weeks (n=199) 
High cholesterol, triglycerides < or = 15 weeks were associated with a 
2.8 fold and 2.0 fold (1.0 – 3.9) increased risk for preterm birth < 34 weeks 
and > or 34 < 37, respectively. Overweight female who delivered < 34 weeks 
had particularly elevated early pregnancy concentrations of cholesterol and 
low density lipoprotein. . There was a reduced triglycerides response in the 
first half of pregnancy among female who delivered < 34 weeks. Results 
indicate that the presence of dyslipidemia in female results spontaneous 
preterm birth our study us similar to it and our result are statistically 
significant. 
In current study out of 300 Antenatal mothers 190 are primi and 210 
are second gravida. Blood collected at 14 – 24 weeks, respectively in 300 
mothers. 
Catov et al., however, suggest that early sPTD (<34 weeks) is 
associated with both high and low pre-pregnancy TC [18]. This same finding 
is supported by Edison et al. during second trimester pregnancy and by Mudd 
et al. only for high TC level [13, 25].  
Another study, Adegbesan-Omilabu Maymunah,1 Okunade Kehinde 
(2012) evaluated Hypercholesterolaemia in pregnancy as a predictor of 
adverse pregnancy outcome). 
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The incidences of the two adverse pregnancy outcomes examined in 
the study (preterm births and low birth weight (LBW) in term neonates) were 
8.0% and 14.4% respectively. Preterm birth was 6.89-times more common in 
mothers with high cholesterol than in control mothers with normal total 
cholesterol level (38.5% versus 5.4%, P=0.029) while LBW was 7.99-times 
more common in mothers with high total maternal cholesterol than in mothers 
with normal cholesterol (87.5% versus 10.5%, P=0.019). 
Inflammation and dyslipidemia related to risk of spontaneous preterm 
birth. 
Serum Cholesterol and Outcome of Delivery 
Sr, Cholesterol No. of cases Outcome of delivery 
Good Preterm 
No % No % 
Normal 281 270 92.6 11 8.4 
Abnormal 19 7 36.8 12 63.2 
Sr.Cholesterol 
Mean 
SD 
 
246.4 
42.86 
 
 
‘p’ < 0.0001 
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All the mothers with normal cholesterol values had 92.6 % good 
outcome whereas of 63.2 % mothers with abnormal cholesterol values had 
preterm deliveries. This difference in statistically significant (p=0.0001). 
A study by Catov JM1, Bodnar LM, Ness RB, Barron SJ, Roberts JM. 
In the Department of Epidemiology, University of Pittsburgh, Pittsburgh, (PA 
15261, USA. jmcst43@pitt.edu) 
The authors considered that inflammation in women with spontaneous 
preterm birth (sPTB) might be related to their metabolic profile, such as lipids, 
and tested this in a nested case-control study from the Pregnancy Exposures 
and Preeclampsia Prevention Study (1997-2001). Cases were women with 
sPTB at 34-<37 weeks (n = 76) or < 34 weeks (n = 33). Controls were 
randomly selected women with term births (n = 228). Early pregnancy 
inflammation (C-reactive protein: > or = 8 microg/ml) and dyslipidemia 
(cholesterol: > 230 mg/dl or triglycerides: > 140 mg/dl) were evaluated in 
serum collected at < 21 weeks. Polycotomous logistic regression was used to 
estimate the effects of dyslipidemia on the risk of sPTB subtypes. After 
adjustment for race, body mass index, periconceptional vitamin use, and 
gestational age at sampling, early pregnancy inflammation (odds ratio = 2.9, 
95% confidence interval (CI): 1.1, 7.2) and dyslipidemia (odds ratio = 2.0, 
95% CI: 1.0, 4.2) were independently associated with sPTB at 34-<37 weeks. 
The presence of both conditions increased risk of sPTB at < 34 weeks 6.4-
fold (95%) 
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These data may have important clinical significance because they 
provide a possible link between preterm delivery and high lipid level. 
Finding by Catov and coworkers26 showed that an elevation in maternal 
cholesterol level early in gestation was associated with an increased risk of 
preterm delivery. This was corroborated by the finding from this present 
cohort study where we reported an elevated risk for preterm birth among 
mothers with high maternal cholesterol. 
There are several limitations to this study. Their demographic, 
socioeconomic or medical characteristics could be small. Our results from the 
specific ethnic groups may not be generalizable to other population. 
Socioeconomic factor such as dietary intake may affect triglycerides and 
cholesterol concentration and risk. 
 Finally, elevated maternal cholesterol levels may play a role in the 
mechanism of under lying preterm delivery or may simply be a marker for 
risk of preterm delivery. 
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SUMMARY 
 This prospective study group included 300 uncomplicated pregnant 
women of 14 to 24 weeks of gestation during the period August 2016 
to July 2017 at Department of obstetrics and  Gynaecology, MMC 
 From all the antenatal mothers included in the study the blood sample 
of serum cholesterol was taken after overnight fasting and were 
followed till delivery. 
 47% of this study population were in the age group of 22 – 24 years. 
(mean – 22.3)  
 46.7% were primis, 53.3% were second gravidas. 
 In this study, we have not seen much influence of age and parity to the 
outcome of delivery. 
 93.7% mothers had normal cholesterol values, 6.3% had elevated 
cholesterol values. 
 The study group with normal cholesterol values had good outcome 
were as 63.2% study group with elevated cholesterol values had 
preterm delivery is statistically significant (p = 0.0001) 
 The mean fetal weight delivered at term are significantly higher than 
those of preterm 
 Among the preterm deliveries, 78.3% babies were admitted in NICU, 
which is statistically significant (p < 0.0001) 
  In the current study cholesterol levels was found to be simple marker 
for preterm delivery 
 
  
 
 
CONCLUSION 
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CONCLUSION 
Serum Cholesterol levels was evaluated in 300 antenatal mothers at 14 
to 24 weeks of gestation with fasting cholesterol levels. 
The findings of the present study showed that serum cholesterol levels 
were found to be elevated in patients who have gone in for preterm labour 
than those gone for term pregnancy. 
Hence, Serum cholesterol levels has been found to be useful simple 
marker for preterm delivery. 
This observation helps us to describe a generic framework for 
combining this screening information for designing a prophylactic 
intervention in future. 
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PROFORMA 
NAME       Age  
IP.No        Unit 
Educational status: 
Income   Occupation   SE Status 
Gravida 
Para        Last Menstrual Period 
(LMP) 
Live        Expected date of 
delivery 
(EDD) 
Abortion       Corrected EDD 
(C.EDD) 
Menstrual Cycle 
Height   Weight   BMI 
        
Booked / Unbooked (UB) 
Immunized / Not 
DOA (Date of Admission) 
Duration of Hospital stay 
DOD (Date of Discharge) 
Period of gestation 
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Present Complaints 
Lower abdominal pain 
Dull low backache 
Vaginal discharge 
Fluid leaking per vaginum 
Fever 
UTI (Urinary Tract Infection) 
URI (Upper Respiratory Tract Infection) 
Bleeding 
Obstetric History 
 Trimester 
 Hyperemesis 
 Exanthematous fever 
 Bleeding 
 Radiation exposure 
 Medication 
 Pain abdomen 
II.Trimester 
 Date of Quickening 
 Bleeding per vaginum 
 History of (H/O) PIH 
 H/O GDM (Gestational Diabetes Mellitus) 
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III.Trimester 
Bleeding per vaginum 
UTI 
Cervico vaginal infection 
Coitus 
Diabetes 
 Hypertension 
 Fever 
 Trauma 
Past Obstetric History 
 Previous child birth  
 H/O abortion 
 H/O Preterm Labour  
 H/O babies with congenital anomalies 
Past Medical History 
 Tuberculosis 
 Bronchial Asthma 
 STD (Sexually Transmitted Diseases) 
 Jaundice 
 Heart Disease 
 Diabetes mellitus  
 Epilepsy 
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 Renal Disease 
General Examination 
Temperature (T)     Pallor  Pedal Edema 
PR BP RR     RS   
 CVS 
Obstetric Examination - Per abdomen 
Investigations 
 Urine analysis 
 Urine culture sensitivity 
        Complete Blood Count 
 Blood urea 
 Sugar  
 S.Creatinine  
 S.Electrolytes 
 HIV, HBsag 
 VDRL 
 ECG 
 CTG 
 USG Abdomen 
 Fetal Outcome 
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ABBREVIATIONS 
 FHR              : Fetal Heart Rate  
FLM   : Fetal Lung Maturity   
GA    : Gestational Age  
GBS    : Group B Streptococcus  
HMD   : Hyaline Membrane Disease  
IVH    : Intra Ventricular haemorrhage  
LN     : Labour Natural  
LMP   : Last Menstrual Period  
LSCS   : Lower Segment Caesarean Section  
MMP   : Matrix MetalloProteinaeses  
NEC    : Nectrotising Enterocolitis  
NICU   : Neonatal Intensive Care Unit  
PROM  : Premature Rupture Of Membranes   
PPROM   : Preterm Premature Rupture Of Membranes  
RDS    : Respiratory Distress Syndrome  
ROM    : Rupture of Membranes  
TIMP :Tissue Inhibitor MetalloProteinaeses 
USG    : Ultra Sono Gram  
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INFORMATION SHEET 
 We are conducting a study on “MEASUREMENT OF SERUM 
CHOLESTEROL LEVELS AS A PREDICTOR OF PRETERM 
DELIVERY” over a period of 1 year which is very valuable to us.  
 The purpose of this study was to evaluate whether serum cholesterol 
associated with preterm labor.   
 The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information will 
be shared.   
 Taking part in this study is voluntary. You are free to decide whether 
to participate in this study or to withdraw at any time; your decision 
will not result in any loss of benefits to which you are otherwise 
entitled.   
 The results of the special study may be intimated to you at the end of 
the study period or during the study if anything is found abnormal 
which may aid in the management or treatment.   
 
 
Signature of investigator      Signature of participant  
Date:   
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S.NO NAME AGE 
OBSTETRIC 
CODE 
LMP EDD 
BLOOD 
COLLECTION 
WEEKS 
S.CHOLESTEROL OUTCOME 
MODE OF 
DELIVERY 
FETAL 
WEIGHT 
(KG) 
NICU 
ADMISSION 
1 SUBHA 24 PRIMI 12.04.16 19.01.17 24 228 TERM LSCS 2.9 NO 
2 HEMAVATHI 22 PRIMI 08.03.16 15.12.16 18 248 TERM NORMAL  2.8 NO 
3 ANITHA 26 G2P1L1 21.05.16 28.02.17 22 285 TERM LSCS 3.2 NO 
4 GOMATHI 23 G2P1L1 26.03.16 02.01.17 16 189 TERM LSCS 2.6 NO 
5 MYTHILI 25 PRIMI 15.04.16 22.01.17 20 233 TERM NORMAL  2.8 NO 
6 LAKSHMI 23 G2P1L1 09.05.16 16.02.17 18 215 TERM NORMAL  2.7 NO 
7 FARIDHA 24 G2P1L1 18.03.16 25.12.16 22 249 TERM LSCS 3 NO 
8 KANIMOZHI 26 PRIMI 22.06.16 29.03.17 20 192 TERM NORMAL  2.8 NO 
9 USHA 23 PRIMI 07.04.16 14.01.17 18 266 TERM NORMAL  2.6 NO 
10 NARAYANI 27 PRIMI 12.05.16 19.02.17 22 276 TERM LSCS 3.1 NO 
11 SUJI 28 G2P1L1 03.04.16 10.01.17 16 168 TERM NORMAL  2.8 NO 
12 RADHA 24 G2P1L1 27.05.16 03.03.17 20 234 TERM LSCS 2.5 NO 
13 SUSEELA 23 G2P1L1 19.05.16 26.02.17 20 206 TERM NORMAL  2.7 N0 
14 SATHYA 21 G2P1L1 02.06.16 09.03.17 18 249 TERM LSCS 2.6 NO 
15 SARANYA 25 PRIMI 07.05.16 14.02.17 22 312 TERM LSCS 2.9 NO 
16 AKILA 27 G2P1L1 09.06.16 16.03.17 24 186 TERM LSCS 2.5 NO 
17 UMA 22 G2P1L1 29.04.16 06.02.17 18 273 TERM NORMAL  2.8 NO 
18 VIJAYA 25 PRIMI 14.05.16 21.02.17 24 201 TERM LSCS 2.4 NO 
19 SAINA 21 PRIMI 12.06.16 19.04.17 22 238 TERM LSCS 3.2 NO 
20 DIVYA 24 G2P1L1 22.06.16 29.03.17 20 177 TERM LSCS 2.9 NO 
21 VASANTHI 21 PRIMI 12.05.16 19.02.17 22 193 TERM NORMAL  2.6 NO 
22 ESWARI 20 PRIMI 09.06.16 16.O3.17 24 254 TERM NORMAL  2.8 NO 
23 RENU 20 G2PIL1 16.0616 23.03.17 18 251  TERM  LSCS 2.5 NO 
24 SHALIMA 23 PRIMI 29.05.16 05.03.17 18 214 PRETERM33 NORMAL  2.8 YES 
25 DEEPA 24 G2PIL1 23.06.16 30.03.17 20 276 TERM NORMAL  2.6 NO 
26 RANGITHA 21 G2PIL1 02.07.16 09.04.17 22 309 TERM LSCS 2.6 NO 
27 SUGANDHI 22 PRIMI 03.06.16 10.03.17 24 289 TERM LSCS 2.7 NO 
28 BHAVANI 23 PRIMI 20.06.16 27.03.17 22 230 TERM NORMAL  2.7 NO 
29 GOWRI 25 PRIMI 12.06.16 12.03.17 18 189 TERM NORMAL  1.9 YES 
30 VANITHA 20 G2PIL1 05.06.16 12.03.17 20 219 TERM NORMAL  2.8 NO 
31 SOWMIYA 21 PRIMI 10.06.16 17.03.17 24 243 TERM NORMAL  2.8 NO 
32 SUNDHARI 23 PRIMI 04.07.16 11.04.17 22 239 TERM NORMAL  2.8 NO 
33 RAMYA 20 G2PIL1 18.07.16 25.04.17 24 217 TERM LSCS 2.9 NO 
34 MOHANA 20 G2PIL1 15.07.16 22.04.17 18 176 PRETERM32 NORMAL  1.8 YES 
35 HEMAVATHI 21 G2PIL1 02.08.16 09.05.17 20 219 TERM NORMAL  2.8 NO 
36 THEENA 22 G2PIL1 13.06.16 20.03.17 22 256 TERM LSCS 3.1 NO 
37 JERINA 23 PRIMI 09.07.16 16.04.17 18 230 TERM NORMAL  2.8 NO 
38 MANGALAM 21 G2PIL1 25.06.16 02.04.17 22 267 TERM NORMAL  2.8 NO 
39 INDHIRA 23 G2PIL1 20.05.16 27.02.17 20 276 PRETERM32 NORMAL  1.8 NO 
40 FARITHABANU 24 PRIMI 01.07.16 08.04.17 24 248 TERM NORMAL  2.8 YES 
41 RASATHI 25 PRIMI 04.08.16 11.05.17 20 298 TERM NORMAL 2.8 NO 
42 THASEEN 20 G2PIL1 18.06.16 25.03.17 22 213 TERM NORMAL 2.8 NO 
43 SANTHA 20 PRIMI 06.07.16 13.04.17 24 256 TERM NORMAL 2.7 NO 
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44 MARY 21 G2PIL1 13.07.16 20.04.17 20 247 TERM LSCS 2.7 NO 
45 ROHINI 22 G2PIL1 15.08.16 22.05.17 18 209 TERM NORMAL 2.7 NO 
46 REKHA 22 PRIMI 18.08.16 25.05.17 22 354 
PRETERM 
34 
NORMAL 2.2 YES 
47 REHIMA 23 G2PIL1 21.06.16 28.03.17 24 254 TERM NORMAL 2.8 NO 
48 SHARMILA 23 PRIMI 30.07.16 10.04.17 20 198 TERM NORMAL 2.8 NO 
49 SHABEBA 24 G2PIL1 08.07.16 15.04.17 18 227 TERM NORMAL 2.7 NO 
50 FATHIMA 25 G2PIL1 10.07.16 17.04.17 22 286 PRETERM36 LSCS 2.4 YES 
51 JANANI 19 G2PIL1 26.06.16 03.04.17 24 233 TERM NORMAL 2.8 NO 
52 RAJI 19 PRIMI 11.07.16 18.04.17 20 256 TERM LSCS 2.7 NO 
53 MURUGAMMA 20 G2PIL1 29.05.16 05.03.17 18 176 PRETERM34 NORMAL 1.8 YES 
54 RASAMMA 20 PRIMI 30.06.16 07.04.17 24 289 TERM LSCS 3.125 NO 
55 PONMANI 21 PRIMI 22.06.16 29.03.17 22 264 TERM NORMAL 2.8 NO 
56 PUSHPA 21 G2PIL1 18.07.16 25.04.17 18 182 PRETERM33 NORMAL 1.3 YES 
57 THILAGAVATHI 23 G2PIL1 31.05.16 07.03.17 20 178 TERM NORMAL 2.8 NO 
58 REKHA 23 G2PIL1 14.06.16 21.03.17 22 402 TERM NORMAL 2.8 NO 
59 PONKODI 26 G2PIL1 23.05.16 30.03.17 24 343 TERM NORMAL 1.8 YES 
60 SARANYA 21 G2PIL1 12.05.16 17.02.17 18 249 TERM NORMAL 2.8 NO 
61 JOTHIKA 22 G2PIL1 16.07.16 23.04.17 18 264 TERM NORMAL 2.8 NO 
62 LAVANYA 23 PRIMI 19.06.16 26.03.17 24 230 TERM NORMAL 2.8 NO 
63 MUNIYAMMAL 24 PRIMI 25.06.16 02.03.17 22 276 TERM NORMAL 1.9 YES 
64 RANI 24 G2PIL1 06.07.16 13.04.17 20 321 TERM NORMAL 2.7 NO 
65 REVATHI 20 G2PIL1 15.07.16 22.04.17 24 243 PRETERM34 LSCS 1.9 YES 
66 JENITHA 20 PRIMI 03.08.16 10.05.17 22 237 PRETERM33 NORMAL 1.3 YES 
67 PONGAVANAM 21 G2PIL1 10.08.16 17.05.17 18 234 TERM LSCS 2.9 YES 
68 MUMTAJ 21 PRIMI 24.07.16 01.05.17 20 276 TERM LSCS 2.9 NO 
69 SHARMILA 23 PRIMI 11.08.16 18.05.17 18 278 TERM NORMAL 1.3 YES 
70 PECHI 19 G2PIL1 05.08.16 12.05.17 24 210 TERM NORMAL 2.8 NO 
71 ELAKIYA 19 G2PIL1 10.07.16 17.04.17 22 240 PRETERM35 NORMAL 2.3 YES 
72 BARANI 24 PRIMI 12.08.16 19.05.17 22 267 TERM NORMAL 2.8 NO 
73 TAMILSELVI 24 G2PIL1 16.06.16 23.03.17 18 245 PRETREM35 NORMAL 2.3 YES 
74 SAGAYAM 25 G2PIL1 06.06.16 13.03.17 24 256 TERM LSCS 3 NO 
75 JASMINE 24 G2PIL1 19.07.16 26.04.17 20 287 TERM NORMAL 1.3 YES 
76 LALITHA 20 PRIMI 21.08.16 28.05.17 22 245 TERM LSCS 2.7 NO 
77 KOKILA 21 G2PIL1 23.06.16 30.03.17 18 256 TERM NORMAL 2.8 NO 
78 ANANDHI 23 G2PIL1 14.06.16 21.03.17 22 287 TERM NORMAL 2.7 NO 
79 SENBAGAM 23 PRIMI 20.07.16 27.03.17 24 245 TERM NORMAL 1.9 YES 
80 LALITHA 21 PRIMI 21.08.16 28.05.17 20 276 TERM NORMAL 2.7 NO 
81 PRABHA 20 G2PIL1 11.06.16 18.04.17 18 221 TERM NORMAL 2.8 NO 
82 GEETHA 20 PRIMI 25.07.16 01.05.17 22 190 TERM NORMAL 2.8 NO 
83 JOTHI 21 PRIMI 19.08.16 26.05.17 24 287 TERM NORMAL 2.8 NO 
84 MANJULA 21 G2PIL1 03.09.16 10.06.17 20 187 TERM NORMAL 2.8 NO 
85 MANGAI 23 G2PIL1 05.07.16 12.04.17 18 280 TERM NORMAL 2.7 NO 
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86 NAGALAKSHMI 25 G2PIL1 12.07.16 19.04.17 24 236 TERM LSCS 2.9 NO 
87 GANGA 20 PRIMI 23.08.16 30.05.17 20 251 TERM LSCS 2.9 NO 
88 ARTHI 20 PRIMI 26.09.16 03.07.17 22 302 PRETERM33 NORMAL 1.3 YES 
89 PRAMA 22 G2PIL1 07.07.16 14.04.17 18 289 TERM LSCS 2.9 NO 
90 SUMITHRA 22 PRIMI 09.08.16 17.05.17 22 213 TERM LSCS 2.9 NO 
91 PARIMALA 21 G2PIL1 02.09.16 09.06.17 24 187 TERM LSCS 2.9 NO 
92 DAICY 23 PRIMI 14.07.16 21.04.17 18 336 PRETERM35 NORMAL 2.3 YES 
93 JERCY 23 G2PIL1 17.08.16 24.05.17 20 245 TERM LSCS 2.7 NO 
94 GIRIJA 19 PRIMI 17.08.16 24.05.17 24 265 TERM NORMAL 2.7 NO 
95 BALA 20 PRIMI 03.09.16 10.06.17 22 176 TERM LSCS 2.7 NO 
96 RAGINI 20 PRIMI 09.09.16 16.06.17 18 234 TERM NORMAL 2.7 NO 
97 ANNALAKSHMI 21 G2PIL1 10.08.16 17.05.17 22 211 PRETERM34 LSCS 1.9 YES 
98 MUTHULAKSHMI 22 G2PIL1 11.07.16 18.04.17 20 287 TERM NORMAL 2.8 NO 
99 RASATHI 21 PRIMI 08.09.17 15.06.17 24 240 TERM NORMAL 2.8 NO 
100 VEEDAVALLI 22 PRIMI 09.08.16 17.05.17 20 243 TERM NORMAL 2.8 NO 
101 GANDHIMADHI 25 PRIMI 13.06.16 20.03.17 18 298 TERM NORMAL 2.8 NO 
102 KALPANA 23 PRIMI 09.06.16 16.03.17 22 248 TERM NORMAL 2.8 NO 
103 MAHALAKSHMI 24 G2PIL1 22.06.16 29.03.17 20 256 PRETERM34 NORMAL 1.8 YES 
104 MANGAI 19 PRIMI 27.07.16 03.04.17 18 287 TERM LSCS 2.9 NO 
105 NAKISBANU 21 G2PIL1 16.08.16 23.05.17 24 280 TERM LSCS 2.9 NO 
106 PACHAYAMMA 22 PRIMI 10.06.16 17.03.17 20 234 TERM LSCS 2.9 NO 
107 ASLIMA 26 PRIMI 19.06.16 26.03.17 22 345 TERM LSCS 2.9 NO 
108 DURGADEVI 20 G2PIL1 23.06.16 30.03.17 18 256 TERM NORMAL 2.8 NO 
109 BAKYAVATHI 20 PRIMI 08.07.16 15.04.17 22 278 PRETERM36 LSCS 2.4 NO 
110 SALIMA 19 PRIMI 13.08.16 20.05.17 24 267 TERM LSCS 3 NO 
111 VALLI 21 PRIMI 04.06.16 11.03.17 20 287 TERM LSCS 2.9 NO 
112 AKSHYA 23 G2PIL1 28.07.16 04.05.17 18 213 TERM LSCS 2.9 NO 
113 INDRA 20 G2PIL1 20.09.16 27.06.17 22 327 TERM LSCS 2.9 NO 
114 ROHINI 21 G2PIL1 03.08.16 10.05.17 20 267 TERM NORMAL 2.8 NO 
115 PREMA 19 PRIMI 08.07.16 15.04.17 24 289 PRETERM33 NORMAL 1.3 YES 
116 CHITRA 20 PRIMI 10.06.16 17.03.17 18 298 TERM NORMAL 2.8 NO 
117 SHAJITHA 20 G2PIL1 30.06.16 07.03.17 22 234 TERM NORMAL 2.8 NO 
118 BEGAM 21 G2PIL1 14.07.16 21.04.17 20 222 TERM NORMAL 2.8 YES 
119 JANAKI 24 PRIMI 12.06.16 19.03.17 24 221 TERM NORMAL 2.8 NO 
120 SUDHA 24 PRIMI 22.06.16 29.03.17 22 256 TERM NORMAL 2.8 NO 
121 SUSELA 21 G2PIL1 12.07.16 19.04.17 18 246 TERM NORMAL 2.8 NO 
122 AYESHA 20 PRIMI 09.06.16 16.03.17 20 324 
PRETERM-
35WKS 
NORMAL 2.1 YES 
123 MUMTAJ 20 G2PIL1 16.0616 23.03.17 24 240 TERM NORMAL 2.8 NO 
124 CELLIN 21 G2PIL1 29.07.16 05.04.17 18 200 TERM LSCS 2.9 NO 
125 JERON 21 PRIMI 23.06.16 30.03.17 24 204 TERM LSCS 3.2 NO 
126 HEMAVATHI 22 PRIMI 02.06.16 09.03.17 20 278 TERM LSCS 2.9 NO 
127 RAM THAI 24 G2PIL1 03.07.16 10.04.17 22 245 TERM LSCS 2.9 NO 
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128 SANKU 25 G2PIL1 20.08.16 27.05.17 24 231 TERM LSCS 2.9 NO 
129 NANDHINI 22 G2PIL1 12.07.16 19.04.17 18 256 TERM NORMAL 2.8 NO 
130 LORETTA 23 PRIMI 05.08.16 12.04.16 22 251 TERM NORMAL 2.8 NO 
131 VIJAYA 24 PRIMI 10.08.16 17.05.17 20 287 TERM NORMAL 2.8 NO 
132 STELLA 20 G2PIL1 04.07.16 11.04.17 24 265 TERM NORMAL 2.8 NO 
133 VASANTHI 21 G2PIL1 18.09.16 25.06.17 20 249 TERM NORMAL 2.8 NO 
134 JAMUNA 23 PRIMI 15.06.16 22.03.17 18 232 TERM NORMAL 2.8 NO 
135 THENMOZHI 21 G2PIL1 02.07.16 09.04.17 22 274 TERM NORMAL 2.8 NO 
136 SUSILA 20 PRIMI 13.09.16 20.06.17 20 245 TERM NORMAL 2.8 NO 
137 SIVAGAMI 20 PRIMI 09.08.16 16.05.17 24 303 TERM NORMAL 2.8 NO 
138 MANI 22 G2PIL1 25.07.16 01.04.17 18 212 TERM NORMAL 2.8 NO 
139 KUMARI 21 PRIMI 20.06.16 27.03.17 22 235 TERM LSCS 2.9 NO 
140 RAMA 23 G2PIL1 01.08.16 08.05.17 20 267 TERM NORMAL 2.8 NO 
141 RANI 21 PRIMI 03.09.16 10.06.17 20 287 TERM LSCS 2.9 NO 
142 SELVI 23 PRIMI 17.07.16 24.04.17 18 245 TERM LSCS 2.9 NO 
143 KUMUTHA 26 G2PIL1 05.08.16 12.05.17 22 265 TERM NORMAL 2.8 NO 
144 KANNAMA 21 PRIMI 14.06.16 21.03.17 24 287 TERM NORMAL 2.8 NO 
145 RASATHI 23 G2PIL1 18.07.16 25.04.17 22 267 TERM NORMAL 2.8 NO 
146 MEENAKSHI 23 PRIMI 19.09.16 26.06.16 18 231 TERM NORMAL 2.8 NO 
147 KARPAGAM 21 PRIMI 22.07.16 29.04.17 20 271 TERM NORMAL 2.8 NO 
148 SANTHI 25 G2PIL1 29.06.16 06.04.17 18 269 TERM LSCS 3.1 NO 
149 HEME 21 G2PIL1 08.08.16 15.05.17 24 265 TERM NORMAL 2.8 NO 
150 MALLIGA 23 G2PIL1 10.09.16 17.06.17 20 236 TERM NORMAL 2.8 NO 
151 CHANDRA 24 G2PIL1 26.07.16 02.05.17 22 301 TERM LSCS 2.9 NO 
152 AMUDHA 21 PRIMI 11.08.16 18.05.17 24 310 TERM LSCS 2.9 NO 
153 RAMA RANI 25 G2PIL1 29.06.16 06.04.17 18 278 TERM NORMAL 2.7 NO 
154 MYTHILI 24 G2PIL1 30.07.16 06.05.17 22 211 TERM LSCS 2.7 NO 
155 POONGODI 21 PRIMI 22.08.16 29.05.17 20 287 TERM NORMAL 2.7 NO 
156 VENNILA 23 G2PIL1 19.06.16 26.03.17 22 256 TERM NORMAL 2.7 NO 
157 RAMANI 24 PRIMI 30.07.16 06.05.17 24 287 TERM NORMAL 2.7 NO 
158 RENUKA 26 PRIMI 13.08.16 20.05.17 20 287 TERM LSCS 2.7 NO 
159 GAYATHRI 25 G2PIL1 24.06.16 01.04.17 18 218 TERM NORMAL 2.7 NO 
160 SREJA 24 PRIMI 11.06.16 18.03.17 24 254 TERM NORMAL 2.7 NO 
161 RAMADEVI 21 G2PIL1 18.09.16 25.06.17 22 265 TERM NORMAL 2.7 NO 
162 POORAKALA 20 PRIMI 20.06.16 27.03.17 18 239 TERM NORMAL 2.7 NO 
163 RADHIKA 21 G2PIL1 24.06.16 01.04.17 20 245 TERM LSCS 2.7 NO 
164 USHA RANI 20 PRIMI 10.07.16 17.04.17 22 231 TERM NORMAL 2.7 NO 
165 DEVI 21 PRIMI 30.07.16 06.04.17 24 180 TERM LSCS 3.3 NO 
166 USHA RANI 23 G2PIL1 06.08.16 13.05.17 18 188 TERM NORMAL 2.8 YES 
167 KAMAKSHI 23 PRIMI 18.08.16 25.05.17 20 204 TERM NORMAL 2.8 NO 
168 ARULMOZHI 25 G2PIL1 14.07.16 21.04.17 22 321 TERM NORMAL 2.8 NO 
169 MAINA 24 G2PIL1 18.08.16 25.05.17 24 239 TERM NORMAL 2.8 NO 
170 GOMATHI 20 PRIMI 10.08.16 17-05.17 20 310 TERM NORMAL 2.8 NO 
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171 SASIKALA 23 G2PIL1 11.07.16 18.04.17 22 239 TERM NORMAL 2.8 NO 
172 SIVAGAMI 21 G2PIL1 10.08.16 17.05.17 18 235 TERM NORMAL 2.8 NO 
173 PAVALAM 21 G2PIL1 17.06.16 23.03.17 24 293 TERM NORMAL 2.8 YES 
174 SUNDARI 22 G2PIL1 05.06.16 30.03.17 20 234 TERM NORMAL 2.8 NO 
175 VALARMATHI 25 G2PIL1 20.07.16 27.04.17 24 211 TERM NORMAL 2.8 NO 
176 PARAMESWARI 20 PRIMI 21.08.16 28.04.17 22 203 TERM NORMAL 2.8 NO 
177 BAKYA 24 G2PIL1 23.06.16 30.03.17 24 243 TERM NORMAL 2.8 NO 
178 BHARATHI 21 PRIMI 14.06.16 21.03.17 22 278 TERM NORMAL 2.8 NO 
179 GAYATHRI 21 PRIMI 20.07.16 27.04.17 20 231 TERM NORMAL 2.7 NO 
180 PADMA 23 G2PIL1 22.08.16 29.o5.17 18 238 TERM LSCS 2.7 NO 
181 RASATHI 22 PRIMI 12.09.16 19.06.17 20 278 TERM NORMAL 2.7 NO 
182 NISHA 27 G2PIL1 28.07.16 04.05.17 18 273 TERM NORMAL 2.7 NO 
183 INDHU 26 PRIMI 22.08.16 29.05.17 24 323 TERM LSCS 2.7 NO 
184 VANI 25 PRIMI 24.09.16 01.o7.17 22 269 TERM NORMAL 2.7 NO 
185 DEVIPRIYA 19 PRIMI 15.07.16 22.04.17 20 261 TERM NORMAL 2.8 NO 
186 PRIYA 22 G2PIL1 19.06.16 26.03.17 18 256 TERM NORMAL 2.7 NO 
187 SATHYA 23 PRIMI 30.08.16 06.06.17 24 203 TERM NORMAL 2.8 NO 
188 MANIMEGALAI 24 PRIMI 27.09.16 04.07.17 22 206 TERM NORMAL 2.8 NO 
189 SRIDEVI 19 G2PIL1 17.07.16 24.04.17 20 243 TERM NORMAL 2.7 NO 
190 VIJAYA 19 G2PIL1 20.08.16 27.05.17 18 192 TERM NORMAL 2.8 NO 
191 SHYLAJA 20 G2PIL1 10.09.16 17.06.17 24 347 
PRE TERM 
~34 WEEKS 
NORMAL 2 YES 
192 SHAKELA 20 PRIMI 18.07.16 25.04.17 22 288 TERM LSCS 2.9 NO 
193 UMA 21 G2PIL1 27.08.16 03.06.17 20 268 TERM LSCS 2.9 YES 
194 SAFEEBA 23 G2PIL1 26.09.16 03.07.17 24 232 TERM LSCS 2.9 NO 
195 LATHA 24 PRIMI 10.08.16 17.05.17 20 195 TERM LSCS 2.9 NO 
196 SATHYA 24 G2PIL1 11.09.16 18.06.17 20 262 TERM NORMAL 2.8 NO 
197 SARASWATHI 21 G2PIL1 19.08.16 26.05.17 22 280 TERM LSCS 3.25 NO 
198 SARITHA 21 PRIMI 20.07.16 27.04.17 24 194 TERM NORMAL 2.8 NO 
199 AMBIKA 23 PRIMI 28.09.16 05.07.17 20 184 TERM NORMAL 2.7 NO 
200 NARMATHA 26 PRIMI 29.08.16 05.06.17 22 198 TERM NORMAL 2.7 NO 
201 SELVI 25 PRIMI 13.06.16 20.03.17 22 232 TERM NORMAL 2.7 NO 
202 SARANYA 23 PRIMI 19.06.16 26.03.17 24 278 TERM NORMAL 2.7 NO 
203 AGALYA 21 G2PIL1 16.07.16 23.04.17 20 329 
PRE TERM 
~32 WEEKS 
NORMAL 2 YES 
204 SANGETA 22 G2PIL1 29.06.16 06.04.17 18 243 TERM NORMAL 2.7 NO 
205 DEEPA 21 PRIMI 28.06.16 05.04.17 22 267 TERM NORMAL 2.7 NO 
206 RAJAKUMARI 19 PRIMI 02.08.16 09.05.17 18 189 TERM NORMAL 2.7 NO 
207 PAVITHRA 19 PRIMI 03.07.16 10.04.17 22 198 TERM LSCS 2.9 NO 
208 BARANI 21 G2PIL1 10.06.16 17.03.17 24 200 TERM LSCS 2.9 NO 
209 SAVITHA 22 PRIMI 14.07.16 21.04.17 20 278 TERM LSCS 3 YES 
210 MALATHI 22 G2PIL1 20.06.16 27.03.17 18 356 TERM LSCS 2.9 NO 
211 RENUKA 21 G2PIL1 10.07.16 17.04.17 22 333 TERM NORMAL 2.7 NO 
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212 PRADEEPA 23 PRIMI 24.07.16 01.05.17 20 234 TERM NORMAL 2.7 NO 
213 SWETHA 20 G2PIL1 18.08.16 25.05.17 24 198 TERM NORMAL 2.8 NO 
214 LAVANYA 20 PRIMI 22.07.16 29.04.17 18 264 TERM NORMAL 2.8 NO 
215 ANITHA 25 G2PIL1 19.08.16 26.04.17 20 244 TERM NORMAL 2.8 NO 
216 ROSE 24 G2PIL1 23.06.16 30.03.17 24 224 TERM NORMAL 2.8 NO 
217 KAMAKSHI 21 PRIMI 21.07.16 28.04.17 24 186 TERM NORMAL 2.7 NO 
218 SUDHA 22 PRIMI 26.06.16 03.03.17 20 254 TERM NORMAL 2.7 NO 
219 RANI 23 PRIMI 20.06.16 27.03.17 18 348 
PRE TERM 
~32 WEEKS 
LSCS 1.95 YES 
220 SEETHA 27 G2PIL1 02.07.16 09.04.17 24 244 TERM NORMAL 2.8 NO 
221 POORNA 21 PRIMI 14.09.16 21.06.17 22 186 TERM LSCS 2.9 NO 
222 ANUJA 20 G2PIL1 20.07.16 27.04.17 20 202 TERM LSCS 2.9 NO 
223 AMMU 21 G2PIL1 18.08.16 25.05.17 24 319 TERM LSCS 2.9 NO 
224 ANUSHYA 21 PRIMI 30.06.16 07.03.17 18 265 TERM NORMAL 2.8 NO 
225 PRIYA 20 G2PIL1 30.07.16 06.03.17 22 278 TERM LSCS 2.9 NO 
226 KRISHNAVENI 20 G2PIL1 16.09.16 23.06.17 18 184 TERM NORMAL 2.8 NO 
227 KAVITHA 21 PRIMI 04.08.16 11.05.17 24 196 TERM LSCS 2.9 NO 
228 CHITHRA 23 G2PIL1 11.07.16 18.04.17 20 212 TERM NORMAL 2.8 NO 
229 KALAIVANI 21 G2PIL1 15.09.16 22.06.17 22 310 TERM LSCS 2.9 NO 
230 DIVIYA 20 G2PIL1 20.06.16 27.03.17 24 186 TERM LSCS 3.1 NO 
231 NATHIYA 22 G2PIL1 14.08.16 21.05.17 18 243 TERM NORMAL 2.7 NO 
232 RAJALAKSHMI 21 PRIMI 24.07.16 31.04.17 22 254 TERM NORMAL 2.7 NO 
233 JAYALAKSHMI 23 G2PIL1 24.08.16 31.05.17 20 259 TERM NORMAL 2.8 NO 
234 SUBHA 25 G2PIL1 02.07.16 09.04.17 18 337 TERM NORMAL 2.8 YES 
235 MANOGRI 24 PRIMI 20.07.16 27.04.17 24 183 TERM NORMAL 2.8 NO 
236 MANGALAM 23 PRIMI 02.07.16 09.04.17 22 198 TERM NORMAL 2.8 NO 
237 CHANDRA 21 G2PIL1 22.08.16 29.05.17 24 224 TERM NORMAL 2.8 NO 
238 SUGANYA 24 PRIMI 16.07.16 23.04.17 22 324 TERM LSCS 2.9 NO 
239 SANGEETHA 23 G2PIL1 10.08.16 17.05.17 20 186 TERM LSCS 3.3 NO 
240 RATHIKA 21 G2PIL1 12.06.16 19.03.17 18 192 TERM LSCS 2.9 NO 
241 SUGANYA 26 G2PIL1 11.06.16 18.03.17 22 240 TERM LSCS 2.9 NO 
242 REVATHI 27 PRIMI 18.06.16 25.03.17 24 244 TERM LSCS 2.9 YES 
243 MALAR 20 G2PIL1 04.09.16 11.06.17 20 254 TERM LSCS 2.9 NO 
244 SUGANTHI 22 G2PIL1 25.08.16 01.06.17 18 250 TERM NORMAL 2.8 NO 
245 SOLAIYAMMA 21 PRIMI 18.06.16 25.03.17 22 182 TERM NORMAL 2.8 NO 
246 JAYANTHI 22 G2PIL1 20.07.16 27.04.17 24 224 TERM NORMAL 2.8 NO 
247 KIRUTHIKA 24 G2PIL1 19.08.16 26.05.17 18 194 TERM LSCS 2.9 NO 
248 KAVYA 23 PRIMI 02.09.16 09.06.17 22 224 TERM LSCS 2.9 NO 
249 SOBANA 21 G2PIL1 08.07.16 15.04.17 24 341 
PRE TERM 
~34 WEEKS 
NORMAL 2.2 YES 
250 TAMIL 23 G2PIL1 11.07.16 18.04.17 20 187 TERM NORMAL 2.7 NO 
251 PUSHPA 19 G2PIL1 12.06.16 19.05.17 18 198 TERM NORMAL 2.6 NO 
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252 THARA 20 G2PIL1 22.08.16 29.05.17 24 322 
PRE TERM 
~32 WEEKS 
LSCS 1.9 YES 
253 SHEELA 21 PRIMI 20.07.16 27.04.17 22 194 TERM NORMAL 2.8 YES 
254 CLARA 26 G2PIL1 03.06.16 10.03.17 20 226 TERM LSCS 2.6 NO 
255 KANIKA 23 G2PIL1 07.07.16 14.04.17 18 208 TERM NORMAL 2.8 NO 
256 KAVITHA 23 PRIMI 10.06.16 17.03.17 20 246 TERM LSCS 3.5 NO 
257 GAYATHRI 23 PRIMI 30.07.16 06.04.17 22 268 TERM NORMAL 2.7 NO 
258 SAROJA 24 G2PIL1 15.06.16 22.03.17 24 278 TERM NORMAL 2.7 NO 
259 KANMANI 20 G2PIL1 24.08.16 01.06.17 20 256 TERM NORMAL 2.7 NO 
260 NANDHINI 19 PRIMI 05.09.16 12.06.17 18 286 TERM NORMAL 2.7 NO 
261 KALAIVANI 19 PRIMI 28.06.16 05.04.17 18 185 TERM LSCS 2.9 NO 
262 JANCY 22 PRIMI 30.07.16 06.04.17 24 189 TERM LSCS 2.9 NO 
263 SIVARANJANI 21 G2PIL1 22.06.16 29.03.17 20 192 TERM LSCS 2.9 NO 
264 RATHI 24 G2PIL1 11.07.16 18.04.17 22 244 TERM NORMAL 2.7 NO 
265 SHALINI 25 PRIMI 12.08.16 19.05.17 18 186 TERM LSCS 2.9 NO 
266 ALAMELU 26 PRIMI 15.07.16 22.04.17 24 230 TERM LSCS 2.9 NO 
267 MARY 19 G2PIL1 13.06.16 20.03.17 22 240 TERM NORMAL 2.8 NO 
268 ELAVARASI 25 PRIMI 15,09.16 22.06.17 20 254 TERM NORMAL 2.7 NO 
269 JAYA 21 G2PIL1 07.09.16 14.06.17 18 198 TERM LSCS 2.7 NO 
270 AJITHA 23 G2PIL1 21.06.16 28.03.17 24 248 TERM NORMAL 2.7 YES 
271 RAJI 22 G2PIL1 30.06.16 07.04.17 18 234 TERM NORMAL 2.7 NO 
272 RAGA 21 G2PIL1 03.10.16 10.07.17 24 188 TERM NORMAL 2.7 NO 
273 SHEELA 22 PRIMI 29.07.16 05.05.17 22 190 TERM NORMAL 2.7 NO 
274 MALLI 23 G2PIL1 30.08.16 06.06.17 20 194 TERM NORMAL 2.8 NO 
275 MARY 19 G2PIL1 12.09.16 19.06.17 22 223 TERM NORMAL 2.6 NO 
276 JAYA 20 PRIMI 07.06.16 13.03.17 18 256 TERM LSCS 2.6 NO 
277 SHANTHI 20 PRIMI 08.06.17 15.03.17 22 326 
PRE TERM 
~32 WEEKS 
NORMAL 1.85 YES 
278 MALIKA 22 G2PIL1 22.07.16 29.04.17 20 286 TERM LSCS 2.9 NO 
279 JAMILA 22 PRIMI 23.08.16 30.05.2017 24 285 TERM NORMAL 2.8 NO 
280 BLESSY 21 G2PIL1 24.06.16 01.04.17 18 245 TERM NORMAL 2.8 NO 
281 SHREYA 23 G2PIL1 04.06.16 11.03.17 20 196 TERM NORMAL 2.8 NO 
282 RAMYA 24 PRIMI 08.06.16 15.03.17 18 220 TERM NORMAL 2.8 NO 
283 VALLI 22 G2PIL1 12.07.16 19.04.17 22 314 TERM NORMAL 2.7 YES 
284 SUJI 25 PRIMI 24.07.16 31.04.17 18 188 TERM LSCS 2.7 NO 
285 ANITHA 20 G2PIL1 30.07.16 06.05.17 24 179 TERM NORMAL 2.7 NO 
286 SUKUMARI 20 PRIMI 02.08.16 09.05.17 22 306 TERM NORMAL 2.8 NO 
287 THARANI 24 G2PIL1 22.08.16 29.05.17 20 250 TERM NORMAL 2.8 NO 
288 BHARATHI 21 PRIMI 02.09.16 09.06.17 24 224 TERM NORMAL 2.8 NO 
289 KALAI 19 PRIMI 09.06.16 16.03.17 20 228 TERM NORMAL 2.8 NO 
290 KOUSALYA 19 G2PIL1 22.06.16 29.03.17 18 218 TERM NORMAL 2.8 NO 
291 NATHIYA 20 G2PIL1 21.08.16 28.05.17 22 210 TERM NORMAL 2.8 NO 
292 KUMARI 26 G2PIL1 03.06.16 10.03.17 24 289 TERM NORMAL 2.8 NO 
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293 RANI 21 PRIMI 04.08.16 11.05.17 20 190 TERM NORMAL 2.8 NO 
294 MANJU 21 G2PIL1 22.09.16 29.06.17 18 230 TERM NORMAL 2.8 NO 
295 VANI 22 G2PIL1 02.06.16 09.03.17 22 335 TERM NORMAL 2.8 NO 
296 SATHYA 23 PRIMI 09.06.16 16.03.17 24 178 TERM NORMAL 2.8 NO 
297 AMBIKA 25 PRIMI 17.07.16 24.04.17 20 238 TERM LSCS 2.9 NO 
298 ANITHA 24 G2PIL1 02.08.16 09.05.17 22 223 TERM LSCS 2.9 NO 
299 MARIYAM 20 PRIMI 19.09.16 26.06.17 24 178 TERM LSCS 2.9 NO 
300 USHA 19 PRIMI 20.08.16 27.05.17 20 200 TERM LSCS 2.9 NO 
 
 
